<div id="readability-page-1"><article>Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) (&#34;BetterLife&#34; or the &#34;Company&#34;), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. (&#34;Cybin&#34;) (NYSE: CYBN), as Executive Chairman and Director.At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.&#34;We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored by a track record of executing multiple successful transactions across diverse markets and therapeutic indications, brings a depth of strategic insight and operational expertise that will meaningfully strengthen BetterLife&#34;, said Ahmad Doroudian, CEO of BetterLife. &#34;Doug's experience navigating complex deal environments and scaling opportunities across jurisdictions will be invaluable as we continue to advance our growth strategy and create long-term shareholder value.&#34;Mr. Drysdale commented, &#34;I am thrilled to join BetterLife as Executive Chairman and Director. Having led Cybin from molecule inception to Phase 3 trials in just three years, I look forward to bringing that same execution focus and global transaction expertise to accelerate BetterLife's growth strategy. Together with the team, we will continue to advance innovative therapies that target neurological disorders and deliver long-term value for patients and shareholders alike.&#34;Pursuant to the appointment of Mr. Drysdale as Executive Chairman, the Company has agreed to grant Mr. Drysdale stock options to purchase 3,500,000 common shares of BetterLife, with an exercise price of $0.065, monthly vesting over 24 months and a ten (10) year term. About BetterLife Pharma BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.For further information, please visit BetterLife Pharma.Cautionary Note Regarding Forward-Looking StatementsNo securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release may contain forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as &#34;will&#34;, &#34;may&#34;, &#34;should&#34;, &#34;anticipate&#34;, &#34;expects&#34; and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.<img id="corporateNewsLogo" src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5696/297144_7bbd785a74da5989_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="52" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5696/297144_7bbd785a74da5989_logo.jpg"/>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297144<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297144/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297144/375"/></article></div>

BetterLife Pharma Inc. has appointed Doug Drysdale as Executive Chairman and Director. Drysdale, previously CEO of Cybin Inc., is recognized for his leadership in advancing mental healthcare. His appointment aims to enhance BetterLife's growth strategy, particularly in developing innovative therapies for neurological disorders. The company will grant him stock options for 3.5 million shares. BetterLife focuses on BETR-001, a non-hallucinogenic LSD derivative for treating neurological disorders, and is exploring further development opportunities for its drug candidate targeting viral infections.

StockTitan

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares US Pharma

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

VG Health

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

VanEck Biotech ETF

ALPS Medical Breakthrough

ChinaAMC SSE Health Care ETF Initiating Fund

Health Care Select Sector SPDR

SPDR S&P Health Equip

E Fund CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Cybin

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director | BETRF Stock News